A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Howell, Sparta

Sponsor
Biodesix

Protocol Number
BDX 00146 Insight

To Learn More Call
201-510-0910

A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer Ramucirumab 10mg/kg q 2 weeks + erlotinib Placebo q 2 weeks + erlotinib

Type of Cancer
Lung

Site
Bethesda

Protocol Number
I4T-MC-JVCY

To Learn More Call
201-510-0910

Phase III, Double-blind, Randomized, Placebo-Controlled Multi-centre, study to assess the efficacy and safety of AZD9291 versus Placebo, in Patients with Epidermal Growth Factor Receptor Mutation Positive Stage IB-IIIA Non-small Cell Lung Resection With or Without Adjuvant Chemotherapy (ADAURA) Carcinoma, following Complete Tumour

Type of Cancer
Lung

Site
Bethesda

Protocol Number
D5164C00001

To Learn More Call
201-510-0910

A Phase 111, Multi-center, Randomized Open-label Study Evaluating the Efficacy and Safety of Atezoluzimab (MPDL3280A,ANTIPD-L1 ANTIBODY) in combination with carboplatin + Nab-paclitaxel vs Carboplatin + Nab-paclitaxel in the treatment of 1st Line naïve patients with Stage 4 Non-Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
GENENTECH

Protocol Number
GO 29537

To Learn More Call
201-510-0910

A Phase III, Randomized, Open-Label, 3-Arm Study Evaluating the Efficacy and Safety of Atezolizumab (Anti-PD-L1_ in Combination with Carboplatin _ Paclitaxel or Atezolizumab in Combination with Carboplain + nabPaclitaxel vs Carboplatin + Paclitaxel in 1st line Stage IV Squamous NSCLC

Type of Cancer
Lung

Site
Freehold, Howell, Little Silver

Sponsor
GENENTECH

Protocol Number
G0 29437

To Learn More Call
201-510-0910

SUSTAIN: A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance after Induction Chemotherapy or as First-line Treatment Alone or in Combination with Standard of Care Therapies

Type of Cancer
Lung

Site
Bethesda

Protocol Number
CA209370

To Learn More Call
201-510-0910

A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients with Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC)

Type of Cancer
Lung

Site
East Brunswick

Sponsor
Clovis

Protocol Number
CO-1686-008 (Tiger X)

Cancer Diagnosis
Non-small cell lung cancer

Phase of Trial
1/2

Study Short Name
Tiger X

To Learn More Call
201-510-0910

A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING ADJUVANT CISPLATIN-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB−IIIA NON−SMALL CELL LUNG CANCER

Type of Cancer
Lung

Site
Freehold, Howell

Sponsor
Genentech

Protocol Number
GO 29527

To Learn More Call
201-510-0910

A Phase III, Open-Label, Randomized Study Of MPDL3280A (Anti-PD-L1 Antibody) In Combination with Carboplatin+Paclitaxel With Or Without Bevacizumab Compared with Carboplatin+Paclitaxel+Bevacizumab In Chemotherapy-Naïve Patients with Stage IV Non-Squamous Non-Small Cell Lung Cancer

Type of Cancer
Lung

Site
East Brunswick, Freehold, Somerville, Sparta

Sponsor
Genentech

Protocol Number
GO29436

Staging
4

Phase of Trial
3

Protocol Title
A Phase 3, Open-Label, Randomized Study Of Mpdl3280a (Anti-Pd-L1 Antibody) In Combination With Carboplatin + Paclitaxel With Or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer.

To Learn More Call
201-510-0910

An observational Study Assessing the Clinical Effectiveness of VeriStrat Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer